Pramipexole
( DrugBank: Pramipexole / KEGG DRUG: Pramipexole )
3 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
20 | 副腎白質ジストロフィー | 1 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
Showing 1 to 3 of 3 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00600873 (ClinicalTrials.gov) | August 200720070800 | 5/1/200820080105 | R(+)PPX High Dose Treatment of ALS | Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Subjects Taking Daily High-Dose R(+) Pramipexole Dihydrochloride for Six Months Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Su ... | Amyotrophic Lateral Sclerosis | Drug: R(+) pramipexole dihydrochloride monohydrate | Bennett, James P., Jr., M.D., Ph.D. | NULL | Completed | 30 Years | 80 Years | Both | 10 | Phase 1/Phase 2 | United States |
2 | NCT00596115 (ClinicalTrials.gov) | October 200520051000 | 5/1/200820080105 | Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) PramipexoleDihydrochloride Monohydrate at 60 ... | Open Label Extension for Treating ALS With R(+) Pramipexole at 60 Milligrams Per Day | Amyotrophic Lateral Sclerosis | Drug: R(+) pramipexole dihydrochloride monohydrate | Bennett, James P., Jr., M.D., Ph.D. | University of Pittsburgh;University of Nebraska | Temporarily not available | 30 Years | 80 Years | Both | N/A | NULL | |
3 | NCT00140218 (ClinicalTrials.gov) | August 200520050800 | 30/8/200520050830 | R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis | Futility Study of R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: R(+) pramipexole dihydrochloride monohydrate | Bennett, James P., Jr., M.D., Ph.D. | University of Pittsburgh | Completed | 21 Years | 85 Years | Both | 30 | Phase 1/Phase 2 | United States |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
Showing 1 to 10 of 125 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR2000039050 | 2020-10-3020201030 | 2020-10-1420201014 | Efficacy of levodopa/carbidopa/entacapone in the replacement of Levodopa /dopa decarboxylase inhibitor in the treatment of 'Wearing-off' in Patients with Parkinson's disease in China: a multicenter, randomized controlled, open study Efficacy of levodopa/carbidopa/entacapone in the replacement of Levodopa /dopa decarboxylase inhibit ... | Efficacy of levodopa/carbidopa/entacapone in the replacement of Levodopa /dopa decarboxylase inhibitor in the treatment of 'Wearing-off' in Patients with Parkinson's disease in China: a multicenter, randomized controlled, open study Efficacy of levodopa/carbidopa/entacapone in the replacement of Levodopa /dopa decarboxylase inhibit ... | Parkinson's Disease | Group 1:adding pramipexole;Group 2:adding LCE; | The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital) | NULL | Pending | 30 | 80 | Both | Group 1:175;Group 2:175; | Phase 4 | China |
2 | ChiCTR2000035564 | 2020-08-1720200817 | 2020-08-1320200813 | Pharmacokinetics and Bioequivalence study of Pramipexole Extended-Release Tablets in Healthy Chinese Volunteers Pharmacokinetics and Bioequivalence study of PramipexoleExtended-Release Tablets in Healthy Chinese ... | Pharmacokinetics and Bioequivalence study of Pramipexole Extended-Release Tablets in Healthy Chinese Volunteers Pharmacokinetics and Bioequivalence study of PramipexoleExtended-Release Tablets in Healthy Chinese ... | Parkinson’s disease | fasting administration group-TR:phase I: Pramipexole Extended-Release Tablets; phase II: Reference preparation;fasting administration group-RT:phase I: Reference preparation: pahse II: Test preparation;high-fat postprandial administration group-TR:phase I: Pramipexole Extended-Release Tablets; phase II: Reference preparation;high-fat postprandial administration group-RT:phase I: Pramipexole Extended-Release Tablets; phase II: Reference preparation; fasting administration group-TR:phase I: PramipexoleExtended-Release Tablets; phase II: Reference pr ... | West China Hospital of Sichuan University | NULL | Recruiting | 18 | 65 | Both | fasting administration group-TR:28;fasting administration group-RT:28;high-fat postprandial administration group-TR:28;high-fat postprandial administration group-RT:28; | Phase 1 | China |
3 | NCT04275492 (ClinicalTrials.gov) | July 24, 202020200724 | 18/11/201920191118 | Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets | Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets | Parkinson's Disease | Drug: Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride);Drug: Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole) Drug: Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexolehy ... | First Affiliated Hospital of Zhejiang University | Hongguan biological pharmaceutical co. | Recruiting | 18 Years | 45 Years | All | 60 | N/A | China |
4 | NCT04249544 (ClinicalTrials.gov) | December 3, 201920191203 | 28/1/202020200128 | Social Decision Making in Parkinson's Disease | Cognitive and Neural Mechanisms of Impaired Social Decision-Making in Parkinson's Patients Taking Dopamine Agonists Cognitive and Neural Mechanisms of Impaired Social Decision-Making in Parkinson's Patients Taking Do ... | Parkinson Disease | Drug: Pramipexole;Drug: Placebo | Vanderbilt University Medical Center | United States Department of Defense | Recruiting | 45 Years | 80 Years | All | 60 | Phase 1 | United States |
5 | ChiCTR1900021708 | 2019-07-0120190701 | 2019-03-0520190305 | Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphi Study for the brain network mechanism of pramipexolein the treatment of tremor-type PD patients base ... | Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphism Study for the brain network mechanism of pramipexolein the treatment of tremor-type PD patients base ... | Parkinson's Disease | Healthy control group:No;tremor-dominant phenotype PD patients group:pramipexole; | Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University | NULL | Pending | 50 | 70 | Both | Healthy control group:80;tremor-dominant phenotype PD patients group:80; | China | |
6 | ChiCTR1900022534 | 2019-06-0120190601 | 2019-04-1520190415 | Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trial Efficacy of entacapone and pramipexolefor non-motor symptoms of Parkinson’s disease: a prospective r ... | Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trial Efficacy of entacapone and pramipexolefor non-motor symptoms of Parkinson’s disease: a prospective r ... | non-motor symptoms of Parkinson’s disease | entacapone group:Patients in the entacapone group will be administered entacapone (Novartis; import drug registration certificate number: H20160680), 10 times per day, 200 mg each time, for 3 weeks. ;pramipexole group:Patients in the pramipexole group will be administered pramipexole (Boehringer-Ingelheim; import drug registration certificate number: 20140918) , 3 times per day, 1 mg each time, for 3 weeks.; entacapone group:Patients in the entacapone group will be administered entacapone (Novartis; import ... | Geriatric Hospital of Hainan | NULL | Pending | 40 | 75 | Both | entacapone group:194;pramipexole group:194; | N/A | China |
7 | NCT03845387 (ClinicalTrials.gov) | February 26, 201920190226 | 15/2/201920190215 | A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease. | A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease. | Parkinson Disease | Drug: KDT-3594;Drug: Pramipexole | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | 79 Years | All | 74 | Phase 2 | Japan |
8 | ChiCTR1800019942 | 2018-12-3120181231 | 2018-12-0920181209 | A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s Disease A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Prami ... | A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s Disease A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Prami ... | Parkinson’s Disease | Experimental group:Zishen Pingchan Granules combined with Pramipexole;Control group:Zishen Pingchan Granules placebo combined with Pramipexole; Experimental group:Zishen Pingchan Granules combined with Pramipexole;Control group:Zishen Pingchan ... | The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital) | NULL | Pending | 30 | 85 | Both | Experimental group:150;Control group:150; | China | |
9 | NCT03521635 (ClinicalTrials.gov) | July 3, 201820180703 | 11/4/201820180411 | The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexoleon the noctUrna ... | A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD) A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing t ... | Parkinson Disease | Drug: Pramipexole SR;Drug: Pramipexole IR | Boehringer Ingelheim | NULL | Completed | 30 Years | N/A | All | 98 | Phase 4 | China |
10 | EUCTR2017-001420-21-DE (EUCTR) | 18/06/201820180618 | 16/02/201820180216 | Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's Disease | A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER. A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Paralle ... | Early Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Early Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkins ... | Product Code: P2B001 INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Product Name: Pramipexole dihydrochloride INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE Product Name: Rasagiline INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Pramipexole dihydrochloride extended-release tablets Product Name: Pramipexole dihydrochloride extended-release tablets INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE Product Code: P2B001 INN or Proposed INN: PRAMIPEXOLEDIHYDROCHLORIDE Other descriptive name: PRAMIPEXO ... | Pharma Two B Ltd | NULL | Not Recruiting | Female: yes Male: yes | 525 | Phase 3 | France;United States;Canada;Spain;Germany |
20. 副腎白質ジストロフィー
臨床試験数 : 61 / 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126
Showing 1 to 1 of 1 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05003648 (ClinicalTrials.gov) | September 202120210900 | 15/7/202120210715 | Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy | Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy: A Key to Improving Sleep and Gait Performance Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy: A Key to Improving Sleep and Gait ... | Adrenoleukodystrophy;Restless Legs Syndrome | Drug: Pramipexole;Drug: Placebo | Massachusetts General Hospital | European Leukodystrophy Association | Not yet recruiting | 18 Years | 75 Years | Female | 24 | Phase 4 | United States;Netherlands |